Sequence: Ac-GALFLAFLAAALSLMGLWSQPKSKRKV-Cya
| Experiment Id | EXP001329 |
|---|---|
| Paper | Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: qu |
| Peptide | MPGα-mNLS |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 2–4 µM optimal (often 4.2 µM used); tested 1.3–12.6 µM |
| Rna Concentration | typically 50 nM (tested 0.005–100 nM) |
| Mixing Ratio | charge ratio (+:-) optimized; best at 15 |
| Formulation Format | non-covalent peptide/siRNA complexes (electrostatic) |
| Formulation Components | MPGα peptide + siRNA in OptiMEM (serum-free) during complexation/transfection |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HTOL and ECV304 GL3 (stable luciferase reporters); HeLa; ECV304 |
| Animal Model | |
| Administration Route | |
| Output Type | luciferase knockdown (RNAi) |
| Output Value | Reported to show no observable difference vs MPGα in luciferase assay (data not shown) |
| Output Units | |
| Output Notes | MPGα-mNLS (Lys→Ser mutation in NLS region) reported similar uptake/functional RNAi as MPGα. |
| Toxicity Notes | MPGα showed no significant toxicity at 2–4 µM (XTT); higher peptide concentrations could be toxic; luciferase normalized to cell viability (FDA assay). |
| Curation Notes |